|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:administered_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:atccode
|
L01 XE24
|
|
gptkbp:brand
|
gptkb:Mekinist
|
|
gptkbp:can_be_combined_with
|
gptkb:dabrafenib
gptkb:cobimetinib
|
|
gptkbp:casnumber
|
871700-17-3
|
|
gptkbp:chemical_formula
|
C19 H19 Cl F3 N3 O3 S
|
|
gptkbp:class
|
antineoplastic agent
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:clinical_use
|
monotherapy or in combination therapy
|
|
gptkbp:composed_by
|
gptkb:chemical_compound
|
|
gptkbp:contraindication
|
pregnancy
lactation
|
|
gptkbp:developed_by
|
gptkb:Glaxo_Smith_Kline
|
|
gptkbp:dosage_form
|
gptkb:tablet
2 mg once daily
|
|
gptkbp:drug_interactions
|
other cancer therapies
|
|
gptkbp:effective_date
|
gptkb:2013
|
|
gptkbp:excretion
|
biliary
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
trametinib
|
|
gptkbp:indication
|
BRAF V600 E or V600 K mutation-positive melanoma
|
|
gptkbp:interacts_with
|
CYP3 A4 inducers
CYP3 A4 inhibitors
|
|
gptkbp:invention
|
patented
|
|
gptkbp:lifespan
|
about 4.5 hours
|
|
gptkbp:marketed_as
|
gptkb:Mekinist
|
|
gptkbp:mechanism_of_action
|
MEK inhibitor
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:monitors
|
0 A0 B1 D1 F1 D
|
|
gptkbp:pdb
|
not applicable
|
|
gptkbp:pharmacokinetics
|
oral bioavailability
inhibition of MEK pathway
|
|
gptkbp:research_areas
|
cancer therapy
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:safety_measures
|
liver function tests
skin examinations
complete blood counts
cardiac function tests
|
|
gptkbp:side_effect
|
gptkb:Cardiology
fatigue
nausea
diarrhea
rash
thromboembolic events
interstitial lung disease
hypersensitivity reactions
elevated liver enzymes
ocular toxicity
|
|
gptkbp:structure
|
gptkb:Bastiladon
|
|
gptkbp:targets
|
gptkb:MEK1
gptkb:MEK2
|
|
gptkbp:used_for
|
treatment of melanoma
|
|
gptkbp:bfsParent
|
gptkb:dabrafenib
gptkb:Cotellic
|
|
gptkbp:bfsLayer
|
6
|